ALFA-1-ANTITRYPSIN PREDICTS SEVERE COVID-19, GASTRIC AND RENAL CANCER IN CONDITIONS OF HYPERGLYCEMIA

IF 0.3 Q4 MEDICINE, RESEARCH & EXPERIMENTAL

World of Medicine and Biology Pub Date : 2023-01-01 DOI:10.26724/2079-8334-2023-1-83-100-105

I. Komarevtseva, S. Smirnov, A. Ihnatova, I. Rudenko, K. Balabanova, I. A. Vyshnitska, V. Komarevtsev

{"title":"ALFA-1-ANTITRYPSIN PREDICTS SEVERE COVID-19, GASTRIC AND RENAL CANCER IN CONDITIONS OF HYPERGLYCEMIA","authors":"I. Komarevtseva, S. Smirnov, A. Ihnatova, I. Rudenko, K. Balabanova, I. A. Vyshnitska, V. Komarevtsev","doi":"10.26724/2079-8334-2023-1-83-100-105","DOIUrl":null,"url":null,"abstract":"Hyperglycemia with or without blood glucose in diabetes range is an emerging finding not uncommonly encountered in patients with COVID-19. This work is to investigate the association between serum alpha-1-antitrypsin, hyperglycemia, and clinical outcomes in COVID-19, and community-acquired pneumonia, gastric cancer and renal cell carcinoma. Alpha-1-antitrypsin levels in serum was determined by the immunoturbidimetric method. We have set the level of alpha-1-antitrypsin in patients with community-acquired pneumonia and COVID-19 with or without hyperglycemia. Levels of alpha-1-antitrypsin in COVID-19 patients with hyperglycemia who survived > those who did not survive. Concentration of alpha-1-antitrypsin levels in COVID-19 men-patients with hyperglycemia who survived was significantly higher than compared with COVID-19 women-patients with hyperglycemia who survived. The obtained data convincingly demonstrate the value of testing the level of alpha-1-antitrypsin in the blood as one of the important indicators of the effectiveness of cancer diagnosis and prognosis.","PeriodicalId":23771,"journal":{"name":"World of Medicine and Biology","volume":"1 1","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World of Medicine and Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26724/2079-8334-2023-1-83-100-105","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 1

Abstract

Hyperglycemia with or without blood glucose in diabetes range is an emerging finding not uncommonly encountered in patients with COVID-19. This work is to investigate the association between serum alpha-1-antitrypsin, hyperglycemia, and clinical outcomes in COVID-19, and community-acquired pneumonia, gastric cancer and renal cell carcinoma. Alpha-1-antitrypsin levels in serum was determined by the immunoturbidimetric method. We have set the level of alpha-1-antitrypsin in patients with community-acquired pneumonia and COVID-19 with or without hyperglycemia. Levels of alpha-1-antitrypsin in COVID-19 patients with hyperglycemia who survived > those who did not survive. Concentration of alpha-1-antitrypsin levels in COVID-19 men-patients with hyperglycemia who survived was significantly higher than compared with COVID-19 women-patients with hyperglycemia who survived. The obtained data convincingly demonstrate the value of testing the level of alpha-1-antitrypsin in the blood as one of the important indicators of the effectiveness of cancer diagnosis and prognosis.

查看原文本刊更多论文

α -1-抗胰蛋白酶预测高血糖状态下严重的covid-19、胃癌和肾癌

糖尿病范围内伴有或不伴有血糖的高血糖是一种新发现，在COVID-19患者中并不罕见。本研究旨在探讨COVID-19患者血清α -1抗胰蛋白酶、高血糖和临床结局与社区获得性肺炎、胃癌和肾细胞癌的关系。免疫比浊法测定血清α -1-抗胰蛋白酶水平。我们对伴有或不伴有高血糖的社区获得性肺炎和COVID-19患者的α -1抗胰蛋白酶水平进行了设定。存活的COVID-19高血糖患者的α -1-抗胰蛋白酶水平与未存活的患者相比。存活的COVID-19男性高血糖患者的α -1抗胰蛋白酶浓度显著高于存活的COVID-19女性高血糖患者。所获得的数据令人信服地证明了检测血液中α -1-抗胰蛋白酶水平作为癌症诊断和预后有效性的重要指标之一的价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World of Medicine and Biology MEDICINE, RESEARCH & EXPERIMENTAL-

自引率

0.00%

发文量